Abstract library

10 results for "Rebours".
#352 Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide
Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.
Conference:
Category: Basic
Presenting Author: Dr maxime palazzo
#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)
Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#536 Orexins Exert a Pro-Apoptotic Effect on Neuroendocrine Tumors (NETs) in an Ex Vivo Culture Model of Tissue Slices
Introduction: Ex vivo culture models of tissue slices are suitable to test the effect of antitumor agents in human tumors. The orexins are neuropeptides binding to G protein-coupled receptors (OX1-R and OX2-R), exerting a pro-apoptotic effect in human colon and pancreatic cancer cell lines.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Maxime Palazzo
#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
Authors: Cros J, Hentic O, Rebours V, Zappa M, ...
#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Olivia Hentic
#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Margot Bucau
#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Margot Bucau
#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours
Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Zappa M, Rebours V, ...
Keywords: MGMT, Streptozotocin, PFS
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors
Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Muller Nelly
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...